Carlo Bosi

Featured in: Favicon

europeanurology.com Favicon

Articles

Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials

Dec 11, 2023 | europeanurology.com | Antonio Cigliola |Valentina Tateo |Carlo Bosi |Alberto Briganti

Vale CL, Fisher DJ, Godolphin PJ, et al. Lancet Oncol 2023;24:783–97The meta-analysis by Vale and colleagues reports the effects of docetaxel added to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) according to patient characteristics. The authors proved that docetaxel prolongs overall survival (OS) in patients with poorer prognosis (high-volume [HV] disease and “bulky” T4 stage tumor).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →